Global Cushing's Syndrome Treatment Market is estimated to be US 676.2 million by 2029 with a CAGR of 8.9% during the forecast period


Posted July 23, 2021 by Nisha0914

The Global Cushing’s Syndrome Treatment Market accounted for US$ 313.0 million in 2020 and is estimated to be US$ 676.2 million by 2029 and is anticipated to register a CAGR of 8.9%%.

 
The Global Cushing’s Syndrome Treatment Market accounted for US$ 313.0 million in 2020 and is estimated to be US$ 676.2 million by 2029 and is anticipated to register a CAGR of 8.9%%. Cushing's syndrome is a hormonal disorder caused by high levels of the hormone cortisol in the body. It’s also known as hypercortisolism. Cortisol is produced in adrenal glands, which are on top of your kidneys. It helps the body:

Maintain blood pressure
Regulate blood sugar
Lower inflammation
But when you have too much cortisol, it can throw off your body's other systems. Most cases of Cushing's syndrome can be cured, though it may take some time for the symptoms to ease up. The condition is more common in women than in men. It's most often seen in people aged 25-40.

The report "Global Cushing’s Syndrome Treatment Market,) By Treatment(surgery, Radiation Therapy, Medication), By Drug type (Ketoconazole, Etomidate, Pasireotide, and Aminoglutethimide), By End-user (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Clinics, e-Commerce/Online Pharmacies) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030”

Key Highlights:

According to the National Center for Biotechnology Information, to normalize the devastating disease effects of hypercortisolemia, it is paramount that successful patient disease management includes individualized, multidisciplinary care, with close collaboration between endocrinologists, neurosurgeons, radiation oncologists, and general surgeons. This commentary will focus on recent advances in the medical treatment of Cushing's, with a focus on newly approved ACTH modulators and glucocorticoid receptor blocker.
According to U.S. food and drug administration on 6th march 2020, The U.S. Food and Drug Administration approved Isturisa (osilodrostat) oral tablets for adults with Cushing’s disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease. Cushing’s disease is a rare disease in which the adrenal glands make too much of the cortisol hormone. Isturisa is the first FDA-approved drug to directly address this cortisol overproduction by blocking the enzyme known as 11-beta-hydroxylase and preventing cortisol synthesis
According to American association of Neurological surgeon, Cushing’s syndrome (also known as Pituitary Adenomas) account for more than 70% in adults and about 60-70% in children and adolescents. Cushing’s syndrome commonly affects adults aged between 20-50 and is more prevalent in females, accounting for about 70% of all cases.

To overcome this syndrome many key players are coming up with new advancements. For instance, in November 2019, Osilodrostat, which is used for the treatment of patient with Cushing syndrome in adults, received positive opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Furthermore, on 6th March 2020, Isturisa (osilodrostat) was approved by the U.S Food and Drug Administration (FDA). Isturisa (osilodrostat) is an oral tablet used in the patients who cannot go for pituitary gland surgery or has not been curative.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Global Cushing's Syndrome Treatment Market,) By Treatment(surgery, Radiation Therapy, Medication), By Drug type (Ketoconazole, Etomidate, Pasireotide, and Aminoglutethimide), By End-user (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Clinics, e-Com)”

To know the upcoming trends and insights prevalent in this market, click the link below:

https://www.prophecymarketinsights.com/market_insight/Global-Cushings-Syndrome-Treatment-Market-3009

Key Market Insights from the report:

The Global Cushing’s Syndrome Treatment Market accounted for US$ 313.0 million in 2020 and is estimated to be US$ 676.2 million by 2029 and is anticipated to register a CAGR of 8.9%. The Global Cushing’s Syndrome Treatment Market is segmented based on the application, treatment, drug type, market and region.

By treatment, the market is segmented in surgery, Radiation Therapy, Medication.
By drug type, the Global Cushing’s Syndrome Treatment Market is segmented into Ketoconazole, Etomidate, Pasireotide, and Aminoglutethimide.
By end-user, the Global Cushing’s Syndrome Treatment Market is segmented into (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Clinics, e-Commerce/Online Pharmacies)
By region, the Global Cushing’s Syndrome Treatment Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the worldwide leader in the Cushing’s syndrome treatment market in terms of revenue, due to the developed healthcare system and health awareness among people.
Competitive Landscape:

The key players operating in the global Cushing’s syndrome treatment market include Pfizer, Corcept Therapeutics Inc., Novartis, Strong Bridge Biopharma, Orphagen Pharmaceuticals, Inc., and HRA Pharma.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

About Prophecy Market Insights

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.



Some Important Points Answered in this Market Report Are Given Below:

Explains an overview of the product portfolio, including product development, planning, and positioning
Explains details about key operational strategies with a focus on R&D strategies, corporate structure, localization strategies, production capabilities, and financial performance of various companies.
Detailed analysis of the market revenue over the forecasted period.
Examining various outlooks of the market with the help of Porter’s five forces analysis, PEST & SWOT Analysis.
Study on the segments that are anticipated to dominate the market.
Study on the regional analysis that is expected to register the highest growth over the forecast period
Key Topics Covered

Introduction
Study Deliverables
Study Assumptions
Scope of the Study
Research Methodology
Executive Summary
Opportunity Map Analysis
Market at Glance
Market Share (%) and BPS Analysis, by Region
Competitive Landscape
Heat Map Analysis
Market Presence and Specificity Analysis
Investment Analysis
Competitive Analysis
To know more

Contact Us:

Sales

Prophecy Market Insights

1 860 531 2701

Email- [email protected]
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Prophecy Market Insights
Phone 08605312701
Business Address Sai Ambience, Kunal Icon Rd, Pimple Saudagar, Pune
Country India
Categories Health
Tags cushings syndrome treatment , cushings syndrome treatment market , global cushings syndrome treatment market , global cushings syndrome treatment market growth , global cushings syndrome treatment market trends
Last Updated July 23, 2021